Table 1.
Characteristics of participants at enrolment. Values are numbers (percentages) unless stated otherwise
| Characteristics | All participants (n=829) | Intervention group (n=415) | Standard care group (n=414) |
|---|---|---|---|
| Mean (SD) age | 52.4 (12.2) | 51.9 (12.4) | 52.9 (12.1) |
| Female sex | 678 (81.8) | 340 (81.9) | 338 (81.6) |
| Marital status: | |||
| Married | 553 (66.7) | 273 (65.8) | 280 (67.6) |
| Single | 129 (15.6) | 68 (16.4) | 61 (14.7) |
| Divorced | 87 (10.5) | 45 (10.8) | 42 (10.1) |
| Widowed | 38 (4.6) | 14 (3.4) | 24 (5.8) |
| Not known | 22 (2.7) | 15 (3.6) | 7 (1.7) |
| Education: | |||
| Primary | 60 (7.2) | 30 (7.2) | 30 (7.2) |
| Secondary | 318 (38.4) | 141 (34.0) | 177 (42.8) |
| University | 439 (53.0) | 235 (56.6) | 204 (49.3) |
| Not known | 12 (1.4) | 9 (2.2) | 3 (0.7) |
| Employment: | |||
| Full time | 375 (45.2) | 192 (46.3) | 183 (44.2) |
| Part time | 109 (13.1) | 53 (12.8) | 56 (13.5) |
| Home maker | 82 (9.9) | 40 (9.6) | 42 (10.1) |
| Unemployed | 67 (8.1) | 34 (8.2) | 33 (8.0) |
| Retired | 173 (20.9) | 82 (19.8) | 91 (22.0) |
| Rather not say | 23 (2.8) | 14 (3.4) | 9 (2.2) |
| Smoking: | |||
| Never | 414 (49.9) | 214 (51.6) | 200 (48.3) |
| Ex-smoker | 280 (33.8) | 133 (32.0) | 147 (35.5) |
| Not every day | 38 (4.6) | 16 (3.9) | 22 (5.3) |
| Every day | 97 (11.7) | 52 (12.5) | 45 (10.9) |
| Alcohol consumption: | |||
| Every day | 32 (3.9) | 18 (4.3) | 14 (3.4) |
| Occasionally | 593 (71.5) | 306 (73.7) | 287 (69.3) |
| Never | 204 (24.6) | 91 (21.9) | 113 (27.3) |
| Country: | |||
| Austria | 140 (16.9) | 71 (17.1) | 69 (16.7) |
| Greece | 259 (31.2) | 127 (30.6) | 132 (31.9) |
| Ireland | 135 (16.3) | 68 (16.4) | 67 (16.2) |
| Norway | 32 (3.9) | 16 (3.9) | 16 (3.9) |
| UK | 263 (31.7) | 133 (32.0) | 130 (31.4) |
| No of comorbidities: | |||
| 0 | 420 (50.7) | 220 (53.0) | 200 (48.3) |
| 1-4 | 393 (47.4) | 188 (45.3) | 205 (49.5) |
| ≥5 | 16 (1.9) | 7 (1.7) | 9 (2.2) |
| Staging*: | |||
| Stage 0 | 3 (0.4) | 2 (0.5) | 1 (0.2) |
| Stage I | 129 (15.6) | 63 (15.2) | 66 (15.9) |
| Stage II | 310 (37.4) | 154 (37.1) | 156 (37.7) |
| Stage III | 310 (37.4) | 157 (37.8) | 153 (37.0) |
| Stage IV† | 21 (2.5) | 10 (2.4) | 11 (2.7) |
| Undefined‡ | 56 (6.8) | 29 (7.0) | 27 (6.5) |
| No of chemotherapy cycles: | |||
| 1 | 3 (0.4) | 3 (0.7) | 0 |
| 2 | 4 (0.5) | 3 (0.7) | 1 (0.2) |
| 3 | 19 (2.3) | 12 (2.9) | 7 (1.7) |
| 4 | 192 (23.2) | 95 (22.9) | 97 (23.4) |
| 5 | 27 (3.3) | 14 (3.4) | 13 (3.1) |
| 6 | 504 (60.8) | 248 (59.8) | 256 (61.8) |
| 7§ | 10 (1.2) | 8 (1.9) | 2 (0.5) |
| 8§ | 65 (7.8) | 30 (7.2) | 35 (8.5) |
| 12§ | 5 (0.6) | 2 (0.5) | 3 (0.7) |
| Median (range) No of chemotherapy cycles | 6 (1-12) | 6 (1-12) | 6 (2-12) |
*
TNM/UICC system for breast/colorectal cancer; Ann Arbor Staging System for haematological cancers.
†
Not an exclusion criterion for participants with haematological cancer.
‡
Data not captured at clinical site before end of trial.
§
Until substantial amendment to study protocol was made to limit patients’ participation to ≤6 chemotherapy cycles, first 80 patients enrolled in trial participated until end of their prescribed chemotherapy protocol, and therefore show as having completed >6 cycles.